Form 4: Vor Biopharma Director Receives Stock Option Grant

Director Michel Detheux was granted 57,162 stock options in Vor Biopharma Inc. as part of standard equity compensation.

Summary

• Director Michel Detheux acquired 57,162 stock options in Vor Biopharma Inc. (VOR).
• The options have an exercise price of $14.09 per share.
• The grant date for the transaction was June 11, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the director's continued service to the company.
• Market price volatility may impact the future value of the granted options.

Future Outlook

The options vest in 36 equal monthly installments starting July 11, 2026, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• The 36-month vesting schedule is a typical retention mechanism used by life sciences companies.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on July 11, 2026.

Key Dates

Keywords

Vor Biopharma, VOR, SEC Form 4, Insider Trading, Stock Options, Director Compensation